Three Departments to Reward Internal Whistleblowers on Quality and Safety of Drugs and Medical Devices

The National Medical Products Administration (NMPA) and two other departments have issued the Announcement on Implementing Rewards for Internal Whistleblowers Reporting Quality and Safety Issues Related to Drugs and Medical Devices (the "Announcement"), with effect from the date of issuance.

The Announcement is applicable to employees and relevant insiders of entities involved in the research, development, manufacturing, operation, and use of drugs and medical devices, as well as providers of third-party online trading platforms for drugs and medical devices, among other organizations. According to the Announcement, internal whistleblowers who report issues that are verified to be true and meet the reward conditions shall be granted rewards by the medical products administrations. The reward levels and the calculation of reward amounts shall be subject to the Interim Measures for Rewards for Whistleblower Reports of Major Violations in the Field of Market Regulation. If the reported major violations involving the safety of drug or medical device have resulted in serious consequences, such as death, severe disability, injuries to multiple individuals, significant property loss, or grave social impact, or if the reporting has helped prevent such major violations, eliminated major safety risks, or assisted in the handling of criminal cases on such major violations, the reward standards may be appropriately increased.



(Source: https://www.nmpa.gov.cn/xxgk/ggtg/zhggtg/20250605145123101.html)

Note: The link to the Chinese official website of the document is for your reference.